1224PQ-TWiST analysis to assess benefit-risk of pembrolizumab in patients with PD-L1-positive advanced or metastatic NSCLC. (23rd October 2018) - Huang, M; Pietanza, M C; Samkari, A; Pellissier, J; Burke, T; Chandwani, S; Kong, F; Pickard, A S